
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Histone Deacetylase 11 (HDAC11) CRISPR Activation Plasmid (h) | sc-402103-ACT | 20 µg | $397.00 | |||
Histone Deacetylase 11 (HDAC11) CRISPR Activation Plasmid (h2) | sc-402103-ACT-2 | 20 µg | $397.00 |
HDAC11 encodes Histone Deacetylase 11, the sole class IV HDAC that modulates chromatin accessibility and transcriptional programs through deacetylation and related acyl-lysine regulation. In human cells, HDAC11 participates in epigenetic control of differentiation, metabolic adaptation, and immune signaling by influencing histone and non-histone substrates that intersect with inflammatory and stress-response pathways. Altered HDAC11 activity has been associated with dysregulated gene expression patterns relevant to oncogenic processes and immune cell functional states. As a result, HDAC11 is widely studied in contexts where chromatin remodeling shapes cell fate decisions and disease-associated transcriptional networks.
Histone Deacetylase 11 (HDAC11) CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous HDAC11 expression without altering the underlying DNA sequence.
Histone Deacetylase 11 (HDAC11) CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the HDAC11 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the HDAC11 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Histone Deacetylase 11 (HDAC11) expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native HDAC11 locus and enabling the study of Histone Deacetylase 11 (HDAC11)-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Histone Deacetylase 11 (HDAC11) pathway restoration in tumor cells with silenced or reduced HDAC11 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.